Cipla reported INR59.27B in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Arca Biopharma USD 34.43M 326K Dec/2025
aTyr Pharma USD 85.61M 58.67M Dec/2025
Bio Path USD 488K 4.07M Sep/2025
Brainstorm Cell Therapeutics USD 2.24M 197K Dec/2025
Capricor Therapeutics USD 29.16M 2.87M Dec/2025
Cara Therapeutics USD 5.94M 983K Sep/2025
Cipla INR 59.27B 1.71B Mar/2026
Dr.Reddys Laboratories INR 74.58B 977M Mar/2026
Esperion Therapeutics USD 83.21M 14.06M Dec/2025
Immunic USD 23.33M 2.67M Dec/2025
Infinity Pharmaceuticals USD 10.7M 1.54M Jun/2023
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Nektar Therapeutics USD 40.9M 44.19M Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Sun Pharmaceuticals INR 114.07B 2.96B Dec/2025
TherapeuticsMD USD 1.41M 50K Jun/2024
UPL INR 156.03B 49.4B Mar/2026